<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Phys Ther</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Phys Ther</journal-id><journal-title-group><journal-title>Brazilian Journal of Physical Therapy</journal-title></journal-title-group><issn pub-type="ppub">1413-3555</issn><issn pub-type="epub">1809-9246</issn><publisher><publisher-name>Associa&#x000e7;&#x000e3;o Brasileira de Pesquisa e P&#x000f3;s-Gradua&#x000e7;&#x000e3;o em
Fisioterapia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26647745</article-id><article-id pub-id-type="pmc">4668337</article-id><article-id pub-id-type="doi">10.1590/bjpt-rbf.2014.0124</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Interval training based on ventilatory anaerobic threshold increases
cardiac vagal modulation and decreases high-sensitivity c-reative protein: randomized
clinical trial in coronary artery disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tamburus</surname><given-names>Nayara Y.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Paula</surname><given-names>Roberta F. L.</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kunz</surname><given-names>Vandeni C.</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>C&#x000e9;sar</surname><given-names>Marcelo C.</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Moreno</surname><given-names>Marlene A.</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>da Silva</surname><given-names>Ester</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="aff1"><label>1</label>N&#x000fa;cleo de Pesquisa em Exerc&#x000ed;cio F&#x000ed;sico, Departamento de Fisioterapia,
Universidade Federal de S&#x000e3;o Carlos (UFSCar), S&#x000e3;o Carlos, SP, Brazil</aff><aff id="aff2"><label>2</label>Faculdade de Ci&#x000ea;ncias da Sa&#x000fa;de, Universidade Metodista de Piracicaba
(UNIMEP), Piracicaba, SP, Brazil</aff><aff id="aff3"><label>3</label>Centro Universit&#x000e1;rio Adventista (UNASP), Engenheiro Coelho, SP,
Brazil</aff><aff id="aff4"><label>4</label>Laborat&#x000f3;rio de Performance Humana, Faculdade de Ci&#x000ea;ncias da Sa&#x000fa;de,
UNIMEP, Piracicaba, SP, Brazil</aff><author-notes><corresp id="c01"><bold>Correspondence Ester da Silva</bold> Universidade Federal de S&#x000e3;o Carlos -
UFSCar Departamento de Fisioterapia N&#x000fa;cleo de Pesquisa em Exerc&#x000ed;cio F&#x000ed;sico Rodovia
Washington Luiz, Km 235 CEP 13565-905, S&#x000e3;o Carlos, SP, Brazil e-mail:
nayaratamburus@hotmail.com, <email>esters@ufscar.br</email></corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="ppub"><season>Nov-Dec</season><year>2015</year></pub-date><volume>19</volume><issue>6</issue><fpage>441</fpage><lpage>450</lpage><history><date date-type="received"><day>02</day><month>8</month><year>2014</year></date><date date-type="rev-recd"><day>21</day><month>1</month><year>2015</year></date><date date-type="accepted"><day>07</day><month>6</month><year>2015</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly
cited.</license-p></license></permissions><abstract><sec><title>Background: </title><p>Autonomic dysfunction and inflammatory activity are involved in the development
and progression of coronary artery disease (CAD), and exercise training has been
shown to confer a cardiovascular benefit. </p></sec><sec><title>Objective:</title><p> To evaluate the effects that interval training (IT) based on ventilatory
anaerobic threshold (VAT) has on heart rate variability (HRV) and high-sensitivity
C-reactive protein (hs-CRP) levels, as well as the relationship between both
levels, in patients with CAD and/or cardiovascular risk factors (RF). </p></sec><sec><title>Method:</title><p> Forty-two men (aged 57.88&#x000b1;6.20 years) were divided into two training groups,
CAD-T (n= 12) and RF-T (n= 10), and two control groups, CAD-C (n= 10) and RF-C
(n=10). Heart rate and RR intervals in the supine position, cardiopulmonary
exercise tests, and hs-CRP levels were measured before and after IT. HRV was
analyzed by spectral and symbolic analysis. The CAD-T and RF-T underwent a 16-week
IT program of three weekly sessions at training intensities based on the VAT. </p></sec><sec><title>Results:</title><p> In the RF-T, cardiac sympathetic modulation index and hs-CRP decreased
(p&#x0003c;0.02), while cardiac parasympathetic modulation index increased (p&#x0003c;0.02).
In the CAD-T, cardiac parasympathetic modulation index increased, while hs-CRP,
systolic, and diastolic blood pressures decreased (p&#x0003c;0.02). Both control groups
showed increase in hs-CRP parameters (p&#x0003c;0.02). There was a strong and
significant association between parasympathetic and sympathetic modulations with
hs-CRP. </p></sec><sec><title>Conclusion:</title><p> The IT program based on the VAT promoted a decrease in hs-CRP associated with
improvement in cardiac autonomic modulation. </p></sec></abstract><kwd-group><kwd>physical therapy</kwd><kwd>coronary disease</kwd><kwd>exercise</kwd><kwd>C-reactive protein</kwd><kwd>heart rate variability</kwd></kwd-group><counts><fig-count count="2"/><table-count count="3"/><equation-count count="0"/><ref-count count="32"/><page-count count="10"/></counts></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Autonomic dysfunction and increased circulating levels of inflammatory biomarkers are
interrelated risk factors implicated in the etiology of coronary artery disease
(CAD)<xref rid="B01" ref-type="bibr">1</xref> and other cardiovascular diseases<xref rid="B02" ref-type="bibr">2</xref>. Recent studies have explored the link between the
autonomic nervous system (ANS) and markers of inflammation<xref rid="B01" ref-type="bibr">1</xref>
<sup>,</sup>
<xref rid="B03" ref-type="bibr">3</xref>. These previous studies have proposed a
relationship between increased high-sensitivity C-reactive protein (hs-CRP) levels and
decreased vagal modulation in patients with CAD, which is also associated with an
increased risk of cardiovascular events and progression of CAD<xref rid="B01" ref-type="bibr">1</xref>
<sup>,</sup>
<xref rid="B03" ref-type="bibr">3</xref>. On the other hand, it has been reported that
the parasympathetic nervous system may inhibit inflammation by discharging acetylcholine
and suppressing the synthesis and release of pro-inflammatory cytokines<xref rid="B04" ref-type="bibr">4</xref>.</p><p>Aerobic exercise training promotes positive autonomic adaptations<xref rid="B05" ref-type="bibr">5</xref>, which may be evidenced by an increase in cardiac parasympathetic
modulation. Among several types of exercise protocol, interval training (IT) has gained
considerable attention as a suitable exercise program for patients with CAD<xref rid="B06" ref-type="bibr">6</xref>
<sup>,</sup>
<xref rid="B07" ref-type="bibr">7</xref>. Several studies suggest that high-intensity IT
promotes more evident cardiovascular adaptions than low and moderate intensity of
exercise in patients with CAD<xref rid="B08" ref-type="bibr">8</xref>
<sup>,</sup>
<xref rid="B09" ref-type="bibr">9</xref>. Regarding autonomic adaptation, Currie et
al.<xref rid="B07" ref-type="bibr">7</xref> reported that neither moderate-intensity
endurance exercise nor novel low-volume high-intensity interval exercise protocol
programs promoted improvements in cardiac autonomic function in patients with CAD. In
contrast, Munk et al.<xref rid="B10" ref-type="bibr">10</xref>showed that high-intensity
IT leads to consistent favorable effects on heart rate variability (HRV).</p><p>Despite these findings, there is a scarcity of clinical data on the effects of IT at
intensities close to the ventilatory anaerobic threshold (VAT) on autonomic modulation
of heart rate (HR). Moreover, it is still unclear whether the increase in
parasympathetic modulation is related to a reduction in inflammation after the IT
program.</p><p>Therefore, the purpose of this study was to evaluate the effects that IT based on the
VAT might have on HRV and hs-CRP levels, as well as the relationship between both
parameters, in patients with CAD and/or cardiovascular risk factors (RF). We
hypothesized that the proposed IT program would improve HRV indices, as evidenced by
increased parasympathetic modulation and decreased sympathetic modulation, in
association with a decrease circulating levels of hs-CRP.</p></sec><sec sec-type="methods"><title>Method</title><sec><title>Subjects</title><p>The study was designed as a randomized clinical trial (ClinicalTrials.gov Identifier:
NCT02313831). A sample of 139 male subjects was interviewed and considered eligible
for the study based on the results of coronary angiography performed at Centro de
Hemodin&#x000e2;mica do Hospital Santa Isabel, Piracicaba, SP, Brazil. All subjects were
screened and classified as either CAD or RF according to the following criteria: CAD
- subjects with angiographic evidence of &#x02265;50% of stenosis in one or more major
coronary vessels or previous coronary artery intervention, such as percutaneous
coronary intervention (PCI) and coronary artery bypass graft (CABG); RF - subjects
without stenosis in coronary vessels (angiographically documented) and without a
history of previous myocardial infarction (MI), PCI or CABG. All subjects presented
three or more cardiovascular RF, such as obesity (body mass index &#x0003e;30
kg/m<sup>2)</sup>, hypertension, diabetes mellitus (type 2 - nonusers of insulin),
dyslipidemia, smoking, and sedentary lifestyle according to the International
Physical Activity Questionnaire (IPAQ) version 6. The exclusion criteria consisted of
MI&#x0003c;6 months, PCI and CABG&#x0003c;3 months, frequent arrhythmias, pulmonary disease,
unstable angina, osteomuscular disorders, insulin-dependent diabetes mellitus,
neoplasia, renal failure, and sequelae associated with stroke.</p><p>In this study, 42 men were selected (22 with CAD and 20 with only cardiovascular RF)
according to the inclusion criteria. The flowchart of the progress of the study is
presented in <xref ref-type="fig" rid="f01">Figure 1</xref>, and subject
characteristics are described in <xref ref-type="table" rid="t01">Table 1</xref>. All
subjects performed a resting 12-lead electrocardiogram and a maximal or
symptom-limited exercise test using the Bruce treadmill protocol under the
supervision of a cardiologist with the objective of pre-exercise screening and risk
stratification for physical activity. Following the exercise testing, a random number
table was used to allocate the CAD subjects to trained group (CAD-T, n=12) or control
group (CAD-C, n=10) and the RF subjects to trained group (RF-T, n=10) or control
group (RF-C, n=10). </p><p>
<fig id="f01" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Flowchart showing patient participation in the study. CAD-T= trained
group with patients with coronary artery disease; CAD-C= control group with
patients with coronary artery disease; RF-T= trained group with patients
with cardiovascular risk factors; RF-C= control group with patients with
cardiovascular risk factors.</title></caption><graphic xlink:href="rbfis-19-06-0441-gf01"/></fig>
</p><p>
<table-wrap id="t01" orientation="portrait" position="float"><label>Table 1.</label><caption><title>Baseline clinical characteristics of the trained and control
groups.</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="3"/></colgroup><thead><tr><th rowspan="2" align="center" colspan="1">
<bold>Variables</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>Trained</bold>
</th><th colspan="3" align="center" rowspan="1">
<bold>Control</bold>
</th></tr><tr><th align="center" rowspan="1" colspan="1">
<bold>RF (n=10)</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>CAD (n=12)</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>RF (n=10)</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>CAD (n=10)</bold>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">58.9&#x000b1;4.0</td><td align="center" rowspan="1" colspan="1">56.2&#x000b1;7.4</td><td align="center" rowspan="1" colspan="1">56.3&#x000b1;6.2</td><td align="center" rowspan="1" colspan="1">60.4&#x000b1;6.1</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Clinical characteristics - number of patients (%)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">Myocardial infarction</td><td align="left" rowspan="1" colspan="1">0(0.0%)</td><td align="left" rowspan="1" colspan="1">4(33.3%)</td><td align="left" rowspan="1" colspan="1">0(0.0%)</td><td align="left" rowspan="1" colspan="1">2(20.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Coronary artery bypass
surgery</td><td align="left" rowspan="1" colspan="1">0(0.0%)</td><td align="left" rowspan="1" colspan="1">4(33.3%)</td><td align="left" rowspan="1" colspan="1">0(0.0%)</td><td align="left" rowspan="1" colspan="1">4(40.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Percutaneous coronary
intervention</td><td align="left" rowspan="1" colspan="1">0(0.0%)</td><td align="left" rowspan="1" colspan="1">8(66.6%)</td><td align="left" rowspan="1" colspan="1">0(0.0%)</td><td align="left" rowspan="1" colspan="1">6(60.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Medication - number of patients (%)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">Beta blockers</td><td align="left" rowspan="1" colspan="1">4(40.0%)</td><td align="left" rowspan="1" colspan="1">7(58.3%)</td><td align="left" rowspan="1" colspan="1">4(40.0%)</td><td align="left" rowspan="1" colspan="1">5(50.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">ACE inhibitors</td><td align="left" rowspan="1" colspan="1">3(30.0%)</td><td align="left" rowspan="1" colspan="1">7(58.3%)</td><td align="left" rowspan="1" colspan="1">7(70.0%)</td><td align="left" rowspan="1" colspan="1">4(40.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypolipidemic agents</td><td align="left" rowspan="1" colspan="1">5(50.0%)</td><td align="left" rowspan="1" colspan="1">10(83.3%)</td><td align="left" rowspan="1" colspan="1">2(20.0%)</td><td align="left" rowspan="1" colspan="1">8(80.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Diuretics</td><td align="left" rowspan="1" colspan="1">1(20.0%)</td><td align="left" rowspan="1" colspan="1">3(25.0%)</td><td align="left" rowspan="1" colspan="1">2(20.0%)</td><td align="left" rowspan="1" colspan="1">2(20.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Antiplatelet agents</td><td align="left" rowspan="1" colspan="1">4(40.0%)</td><td align="left" rowspan="1" colspan="1">10(83.3%)</td><td align="left" rowspan="1" colspan="1">6(60.0%)</td><td align="left" rowspan="1" colspan="1">9(90.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypoglycemic agents</td><td align="left" rowspan="1" colspan="1">0(0.0%)</td><td align="left" rowspan="1" colspan="1">1(8.3%)</td><td align="left" rowspan="1" colspan="1">2(20.0%)</td><td align="left" rowspan="1" colspan="1">2(20.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Risk factor - number of patients (%)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking</td><td align="left" rowspan="1" colspan="1">1(10.0%)</td><td align="left" rowspan="1" colspan="1">3(25.0%)</td><td align="left" rowspan="1" colspan="1">3(30.0%)</td><td align="left" rowspan="1" colspan="1">1(10.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Sedentary lifestyle (IPAQ)</td><td align="left" rowspan="1" colspan="1">10(100.0%)</td><td align="left" rowspan="1" colspan="1">12(100.0%)</td><td align="left" rowspan="1" colspan="1">10(100.0%)</td><td align="left" rowspan="1" colspan="1">10(100.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dyslipidemia</td><td align="left" rowspan="1" colspan="1">7(70.0%)</td><td align="left" rowspan="1" colspan="1">10(83.3%)</td><td align="left" rowspan="1" colspan="1">3(30.0%)</td><td align="left" rowspan="1" colspan="1">9(90.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension (140/90 mHg)</td><td align="left" rowspan="1" colspan="1">5(50.0%)</td><td align="left" rowspan="1" colspan="1">8(66.6%)</td><td align="left" rowspan="1" colspan="1">7(70.0%)</td><td align="left" rowspan="1" colspan="1">7(70.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Obesity (BMI &#x02265; 30
kg/m<sup>2)</sup>
</td><td align="left" rowspan="1" colspan="1">1(10.0%)</td><td align="left" rowspan="1" colspan="1">5(41.6%)</td><td align="left" rowspan="1" colspan="1">3(30.0%)</td><td align="left" rowspan="1" colspan="1">3(30.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus</td><td align="left" rowspan="1" colspan="1">0(0.0%)</td><td align="left" rowspan="1" colspan="1">1(8.3%)</td><td align="left" rowspan="1" colspan="1">2(20.0%)</td><td align="left" rowspan="1" colspan="1">2(20.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Metabolic variables</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglycerides (mg/dL)</td><td align="left" rowspan="1" colspan="1">119.9&#x000b1;59.1</td><td align="left" rowspan="1" colspan="1">154.2&#x000b1;70.0</td><td align="left" rowspan="1" colspan="1">138.8&#x000b1;44.4</td><td align="left" rowspan="1" colspan="1">153.1&#x000b1;74.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Total cholesterol (mg/dL)</td><td align="left" rowspan="1" colspan="1">177.7&#x000b1;46.7</td><td align="left" rowspan="1" colspan="1">172.2&#x000b1;50.1</td><td align="left" rowspan="1" colspan="1">164.8&#x000b1;24.0</td><td align="left" rowspan="1" colspan="1">171.6&#x000b1;22.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting glucose (mg/dL)</td><td align="left" rowspan="1" colspan="1">93.2&#x000b1;7.5</td><td align="left" rowspan="1" colspan="1">98.2&#x000b1;10.9</td><td align="left" rowspan="1" colspan="1">90.0&#x000b1;10.0</td><td align="left" rowspan="1" colspan="1">97.2&#x000b1;12.1</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL cholesterol (mg/dL)</td><td align="left" rowspan="1" colspan="1">48.1&#x000b1;20.1</td><td align="left" rowspan="1" colspan="1">40.7&#x000b1;10.5</td><td align="left" rowspan="1" colspan="1">39.9&#x000b1;11.6</td><td align="left" rowspan="1" colspan="1">39.1&#x000b1;9.8</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL cholesterol (mg/dL)</td><td align="left" rowspan="1" colspan="1">97.2&#x000b1;29.5</td><td align="left" rowspan="1" colspan="1">105.6&#x000b1;34.3</td><td align="left" rowspan="1" colspan="1">100.7&#x000b1;17.9</td><td align="left" rowspan="1" colspan="1">98.7&#x000b1;26.4</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Ventilatory anaerobic threshold</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">VO<sub>2</sub>(mL.kg<sup>-1</sup>.min<sup>-1)</sup>
</td><td align="left" rowspan="1" colspan="1">14.5&#x000b1;2.4</td><td align="left" rowspan="1" colspan="1">13.50&#x000b1;2.14</td><td align="left" rowspan="1" colspan="1">14.38&#x000b1;2.06</td><td align="left" rowspan="1" colspan="1">13.15&#x000b1;3.33</td></tr><tr><td align="left" rowspan="1" colspan="1">VO<sub>2</sub>
(L.min<sup>-1)</sup>
</td><td align="left" rowspan="1" colspan="1">1.15&#x000b1;0.24</td><td align="left" rowspan="1" colspan="1">1.12&#x000b1;0.25</td><td align="left" rowspan="1" colspan="1">1.14&#x000b1;0.28</td><td align="left" rowspan="1" colspan="1">1.08&#x000b1;0.20</td></tr><tr><td align="left" rowspan="1" colspan="1">HR (bpm)</td><td align="left" rowspan="1" colspan="1">105.6&#x000b1;15.1</td><td align="left" rowspan="1" colspan="1">106.9&#x000b1;12.7</td><td align="left" rowspan="1" colspan="1">115.7&#x000b1;22.3</td><td align="left" rowspan="1" colspan="1">103.4&#x000b1;24.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Workload (W)</td><td rowspan="2" align="left" colspan="1">82.6&#x000b1;28.0</td><td rowspan="2" align="left" colspan="1">80.2&#x000b1; 6.8</td><td rowspan="2" align="left" colspan="1">84.3&#x000b1;24.3</td><td rowspan="2" align="left" colspan="1">81.7&#x000b1;17.3</td></tr><tr><td colspan="5" align="justify" rowspan="1">
</td></tr></tbody></table><table-wrap-foot><fn id="TFN01"><p>Values are represented as mean &#x000b1; SD, except where indicated. CAD =
coronary artery disease; RF = risk factor; ACE = angiotensin converting
enzyme; IPAQ = International Physical Activity Questionnaire; HDL =
high-density lipoprotein; LDL = low-density lipoprotein; VO2 = oxygen
consumption; HR = heart rate; bpm = beats per minute; W = watts.</p></fn></table-wrap-foot></table-wrap>
</p><p>All subjects signed an informed consent form prior to participating in the study,
which was approved by the Ethics Committee of Universidade Metodista de Piracicaba
(UNIMEP), Piracicaba, SP, Brazil (Protocol 34/12).</p></sec><sec><title>Experimental procedures</title><p>All experimental procedures were performed in the morning. The room temperature and
relative air humidity of the testing laboratory were kept at 23&#x000b0;C and between 40% and
60%, respectively. Before the experimental procedures, all subjects were familiarized
with the equipment and experimental protocol to reduce anxiety. They were then
instructed to abstain from stimulants (coffee, tea, soft drinks) and alcoholic
beverages, avoid exhausting physical activity in the 24 h prior to the test, and have
a light meal at least 2 h before the experiment.</p></sec><sec><title>Blood plasma parameters</title><p>After an overnight 12-h fast, venous blood samples were drawn to analyze the
following parameters: fasting glucose, total cholesterol (using the autoanalyzer
method), high-density lipoprotein (HDL) and low density lipoprotein (LDL) cholesterol
(using enzymatic colorimetry), triglycerides (using automated enzymatic methods), and
hs-CRP (with the nephelometric method).</p></sec><sec><title>Measurement and analysis of HRV</title><p>Each subject's HR and RR intervals were measured for 15 minutes with a digital
telemetry system consisting of a transmitter placed on the chest and a HR monitor
(Polar<sup>&#x000d2;</sup> S810i; Polar Electro Oy, Kempele, Finland) previously validated
by Gamelin et al.<xref rid="B11" ref-type="bibr">11</xref>. The measurements were
obtained with the subjects in the supine position while breathing spontaneously (i.e.
&#x02248; 14 breaths per minute).</p><p>After transferring the data to the computer, 300 consecutive beats were selected
after the length of greatest stability was chosen from the central region of the time
series. The initial and final RR intervals were discarded. The HRV was evaluated
based on spectral<xref rid="B12" ref-type="bibr">12</xref> and symbolic analyses<xref rid="B13" ref-type="bibr">13</xref>. The same sequence was used for both the
spectral and the symbolic analysis. Detailed procedures for HRV analysis were as
previously described<xref rid="B12" ref-type="bibr">12</xref>
<sup>,</sup>
<xref rid="B13" ref-type="bibr">13</xref>.</p></sec><sec><title>Cardiopulmonary exercise test (CPET)</title><p>Each subject underwent submaximal CPET on a cycle ergometer with an electromagnetic
brake (Corival V2, Lode B.V., Groningen, The Netherlands) to determine the VAT before
IT. Workload increments were determined for each subject according to the formula
proposed by Wasserman et al.<xref rid="B14" ref-type="bibr">14</xref> (Workload
increase (W) = [(height - age) x 20] - [150 + (6 x body mass)]/100). CPET was
performed with 1 min baseline; 4 min unloaded cycling, followed by the workload
increments. The test was interrupted when the patients had symptom- and/or
sign-limited HR (pallor, unusual sweating patterns, nausea, vomiting, physical
exultation, dimmed or blurred vision, dyspnea, and abnormal response of SBP and HR in
progressive workloads) or attained submaximal HR (85% of maximum HR)<xref rid="B15" ref-type="bibr">15</xref>. Ventilatory and metabolic measurements were
obtained on a breath-by-breath basis using a metabolic analyzer (CPX-D, Medical
Graphics, St. Paul, MN, USA). HR was monitored throughout the test using a 12-lead
electrocardiogram (Welch Allyn CardioPerfect Workstation, Skaneateles Falls, NY,
USA).</p><p>The VAT was determined from a loss of parallelism between VO<sub>2</sub> (oxygen
consumption) and VCO<sub>2</sub> (carbon dioxide output) by three properly trained
observers, as previously described by Zamun&#x000e9;r et al.<xref rid="B16" ref-type="bibr">16</xref> and Higa et al.<xref rid="B17" ref-type="bibr">17</xref>.</p></sec><sec><title>Interval training program</title><p>The IT program was individualized and administered three times per week (on alternate
days) for a 16-week period. Each exercise session lasted approximately 60 min and was
divided into three parts as follows: <bold>1) Warm-up</bold> (10 min) including
stretching, calisthenics, and low-intensity exercises (walking); <bold>2) Exercise
training protocol</bold> (<xref ref-type="fig" rid="f02">Figure 2</xref>)
performed on a stationary cycle ergometer (30-40 min)<xref rid="B18" ref-type="bibr">18</xref>
<sup>,</sup>
<xref rid="B19" ref-type="bibr">19</xref> and was divided into 6 steps: <bold>Step
1</bold> - 5-min at moderate intensity with the aim of reaching 80% of the
workload attained at VAT; <bold>Step 2 and 4</bold> - 5-min and progressing up to
10-min at moderate-high intensity with the aim of reaching 100% of the workload
attained at VAT; <bold>Step 3 and 5</bold> - 5-min at moderate to high intensity with
the aim of reaching 110% of the workload attained at VAT; <bold>Step 6 -</bold> 5-min
at moderate intensity with the aim of reaching 70% of workload attained at VAT. The
moderate and moderate-high intensities were comprised, thus eliciting the aerobic and
the anaerobic metabolism. <bold>3) Cool-down</bold> (10 min) consisted of stretching
and respiratory exercises to allow the BP and HR values to return to their near-basal
values. Polar HR monitors (Polar<sup>&#x000d2;</sup> S810i; Polar Electro Oy, Kempele,
Finland) were worn during each exercise session to ensure that patients exercised at
the targeted intensity. </p><p>
<fig id="f02" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Visual presentation of intensity levels and duration performed during of
interval training. VAT= ventilatory anaerobic threshold.</title></caption><graphic xlink:href="rbfis-19-06-0441-gf02"/></fig>
</p><p>The intensity of the physical training was adjusted on a monthly basis, following the
methodology proposed by Sirol et al.<xref rid="B18" ref-type="bibr">18</xref> and
Pithon et al.<xref rid="B19" ref-type="bibr">19</xref>, by determining the anaerobic
threshold from the HR response. HR response was analyzed during discontinuous
exercise testing on cycle ergometer in each workload applied. HR data behavior was
analyzed based in mathematical and statistical models, whereby evaluated the loss of
stability of the HR response (decreasing, stable, or increasing response as a
function of time). A positive slope and statistically significant was considered as
workload at VAT level, which has been attributed to the beginning of the predominance
of sympathetic activation. Thus, the physical training intensity levels were adjusted
based on the HR data at the power output level corresponding to the positive slope of
HR.</p></sec><sec><title>Statistical analysis</title><p>Based on the pilot study (n=6), the sample size was calculated using GPower software
(version 3.1) considering a 5% chance of type I error, a 2-sided test, and a power of
80% power, according to Lara Fernandes et al.<xref rid="B20" ref-type="bibr">20</xref>. The outcome variable considered for the sample size calculation was
hs-CRP, based on analysis of variance (repeated measures; within between
interaction), which provided an effect size (ES) of 0.77. A final sample of 10
patients in each group was suggested. According to the frequency distribution
analysis (Shapiro-Wilk test), the data did not show a normal distribution. Baseline
clinical characteristics are presented as means &#x000b1; standard deviation. Hemodynamic
variables at rest, HRV indices, and hs-CRP levels are presented as medians
(interquartile range). The Mann-Whitney test was performed for intergroup comparison,
and the Wilcoxon test was used for intragroup comparison. To adjust for multiple
comparisons, the Bonferroni correction was used at a signi&#x0fb01;cance level of p&#x0003c;0.02.
The ES for each mean difference was calculated using Cohen's d<xref rid="B21" ref-type="bibr">21</xref>. The thresholds used for interpretation were as follows:
values &#x0003e;0.2 to 0.5 = small ES, &#x0003e;0.5 to 0.8 = medium ES, and &#x0003e;0.8 = large
ES.</p><p>Analysis of covariance (ANCOVA) and linear regression were used to assess the
relationship between HRV indices and hs-CRP (dependent variables), as well as
covariates (independent variables) such as clinical variables, use of medication, and
risk factors (<xref ref-type="table" rid="t01">Table 1</xref>). The correlation
between HRV indices and hs-CRP was analyzed using partial correlation adjusted for
the following covariates: clinical variables, use of medication, and risk factors,
based on their significance in the covariance test (ANCOVA). The correlation
coefficient was calculated (r=0.40 to 0.50, weak correlation; r=0.6 to 0.7, moderate
correlation; r=&#x0003e;0.8, strong correlation). Significance was established at the
level of p&#x0003c;0.05 (&#x003b1;=5%). </p><p>All statistical analyses were performed using the software packages STATISTICA for
Windows 7.0 and R version 2.9.0 for Windows.</p></sec></sec><sec sec-type="results"><title>Results</title><p>There were no changes in anthropometrics characteristics at baseline and after follow-up
in trained and control groups. At baseline, the resting systolic BP, diastolic BP and HR
did not differ significantly among trained and control groups (p&#x0003e;0.02). After IT, a
significant decrease in resting systolic and diastolic BP values was noted in the CAD-T
group (p&#x0003c;0.02). Moreover, systolic (p&#x0003c;0.02) and diastolic BP (p&#x0003c;0.02) values
were significantly lower in the RF-T group compared to the RF-C group. The ES was
considered large for systolic and diastolic BP. Neither of the control groups showed any
detectable changes after 16 weeks (p&#x0003e;0.02) (<xref ref-type="table" rid="t02">Table
2</xref>). </p><p>
<table-wrap id="t02" orientation="portrait" position="float"><label>Table 2.</label><caption><title>Hemodynamic variables at rest, heart rate variability indices, and
high-sensitivity C-reactive protein levels of the groups studied.</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th colspan="1" rowspan="3" align="center">
<bold>Variables</bold>
</th><th colspan="4" align="center" rowspan="1">
<bold>Trained</bold>
</th><th colspan="4" align="center" rowspan="1">
<bold>Control</bold>
</th><th colspan="2" align="center" rowspan="1">
<bold>Trained vs Control</bold>
</th></tr><tr><th align="center" rowspan="1" colspan="1">
<bold>Before</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>After</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>p</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>ES</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>Before</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>After</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>p</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>ES</bold>
</th><th rowspan="2" align="center" colspan="1">
<bold>p for before</bold>
</th><th rowspan="2" align="center" colspan="1">
<bold>p for after</bold>
</th></tr><tr><th colspan="4" align="center" rowspan="1">
<bold>RF-T (n=10)</bold>
</th><th colspan="4" align="center" rowspan="1">
<bold>RF-C (n=10)</bold>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Height (cm)</td><td align="center" rowspan="1" colspan="1">169(7) </td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">169(8) </td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1"> Weight (kg) </td><td align="center" rowspan="1" colspan="1">79.2(8.8)</td><td align="center" rowspan="1" colspan="1">78.0(12.6)</td><td align="center" rowspan="1" colspan="1">0.03 </td><td align="center" rowspan="1" colspan="1">0.26 </td><td align="center" rowspan="1" colspan="1">74.0(21.0)</td><td align="left" rowspan="1" colspan="1">77.5(24.6)</td><td align="center" rowspan="1" colspan="1">0.30 </td><td align="center" rowspan="1" colspan="1">0.05</td><td align="center" rowspan="1" colspan="1">0.73</td><td align="center" rowspan="1" colspan="1">0.73</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m2)</td><td align="center" rowspan="1" colspan="1">26.7(2.5)</td><td align="center" rowspan="1" colspan="1">26.1(2.7) </td><td align="center" rowspan="1" colspan="1">0.03 </td><td align="center" rowspan="1" colspan="1">0.41 </td><td align="center" rowspan="1" colspan="1">26.3(5.6) </td><td align="center" rowspan="1" colspan="1">27.5(5.4)</td><td align="center" rowspan="1" colspan="1">0.30 </td><td align="center" rowspan="1" colspan="1">0.14 </td><td align="center" rowspan="1" colspan="1">0.79</td><td align="center" rowspan="1" colspan="1">0.73 </td></tr><tr><td align="left" rowspan="1" colspan="1">SBP (mmHg)</td><td align="center" rowspan="1" colspan="1">130(17.5)</td><td align="center" rowspan="1" colspan="1">120(7.5)</td><td align="center" rowspan="1" colspan="1">0.03</td><td align="center" rowspan="1" colspan="1">0.67</td><td align="center" rowspan="1" colspan="1">127(9.5)</td><td align="center" rowspan="1" colspan="1">130(11.2)</td><td align="center" rowspan="1" colspan="1">0.05</td><td align="center" rowspan="1" colspan="1">0.53</td><td align="center" rowspan="1" colspan="1">0.85</td><td align="center" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">DBP (mmHg) </td><td align="center" rowspan="1" colspan="1">85(10)</td><td align="center" rowspan="1" colspan="1">80(3.7)</td><td align="center" rowspan="1" colspan="1">0.03</td><td align="center" rowspan="1" colspan="1">0.76</td><td align="center" rowspan="1" colspan="1">89(10)</td><td align="center" rowspan="1" colspan="1">88(8.7)</td><td align="center" rowspan="1" colspan="1">0.22</td><td align="center" rowspan="1" colspan="1">0.33</td><td align="center" rowspan="1" colspan="1">0.85</td><td align="center" rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" rowspan="1" colspan="1"> HR (bpm) </td><td align="center" rowspan="1" colspan="1">61(17)</td><td align="center" rowspan="1" colspan="1">67(11)</td><td align="center" rowspan="1" colspan="1">0.79</td><td align="center" rowspan="1" colspan="1">0.03</td><td align="center" rowspan="1" colspan="1">63(11)</td><td align="center" rowspan="1" colspan="1">66(14)</td><td align="center" rowspan="1" colspan="1">0.08</td><td align="center" rowspan="1" colspan="1">0.41</td><td align="center" rowspan="1" colspan="1">0.91</td><td align="center" rowspan="1" colspan="1">0.57</td></tr><tr><td colspan="11" align="left" rowspan="1">Spectral and symbolic indices</td></tr><tr><td align="left" rowspan="1" colspan="1">LF (nu)</td><td align="center" rowspan="1" colspan="1">0.55(0.24)</td><td align="center" rowspan="1" colspan="1">0.46(0.24)</td><td align="center" rowspan="1" colspan="1">0.28</td><td align="center" rowspan="1" colspan="1">0.36</td><td align="center" rowspan="1" colspan="1">0.63(0.39)</td><td align="center" rowspan="1" colspan="1">0.73(0.07)</td><td align="center" rowspan="1" colspan="1">0.20</td><td align="center" rowspan="1" colspan="1">0.62</td><td align="center" rowspan="1" colspan="1">0.68</td><td align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">HF (nu)</td><td align="center" rowspan="1" colspan="1">0.44(0.24)</td><td align="center" rowspan="1" colspan="1">0.53(0.24)</td><td align="center" rowspan="1" colspan="1">0.28</td><td align="center" rowspan="1" colspan="1">0.36</td><td align="center" rowspan="1" colspan="1">0.36(0.39)</td><td align="center" rowspan="1" colspan="1">0.26(0.07)</td><td align="center" rowspan="1" colspan="1">0.20</td><td align="center" rowspan="1" colspan="1">0.62</td><td align="center" rowspan="1" colspan="1">0.68</td><td align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">0V%</td><td align="center" rowspan="1" colspan="1">29.2(20.2)</td><td align="center" rowspan="1" colspan="1">14.7(19.6)</td><td align="center" rowspan="1" colspan="1">0.009</td><td align="center" rowspan="1" colspan="1">0.67</td><td align="center" rowspan="1" colspan="1">25.0(10.5)</td><td align="center" rowspan="1" colspan="1">31.1(9.2)</td><td align="center" rowspan="1" colspan="1">0.24</td><td align="center" rowspan="1" colspan="1">0.22</td><td align="center" rowspan="1" colspan="1">0.63</td><td align="center" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">2UV%</td><td align="center" rowspan="1" colspan="1">16.8(10.5)</td><td align="center" rowspan="1" colspan="1">24.2(14.3)</td><td align="center" rowspan="1" colspan="1">0.005</td><td align="center" rowspan="1" colspan="1">0.76</td><td align="center" rowspan="1" colspan="1">12.2(23.4)</td><td align="center" rowspan="1" colspan="1">10.3(6.1)</td><td align="center" rowspan="1" colspan="1">0.18</td><td align="center" rowspan="1" colspan="1">0.64</td><td align="center" rowspan="1" colspan="1">0.73</td><td align="center" rowspan="1" colspan="1">0.01</td></tr><tr><td colspan="11" align="left" rowspan="1">Inflammatory marker</td></tr><tr><td align="left" rowspan="1" colspan="1">hs-CRP (mg/dL) </td><td align="center" rowspan="1" colspan="1">0.18(1.0)</td><td align="center" rowspan="1" colspan="1">0.04(0.05)</td><td align="center" rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">0.37</td><td align="center" rowspan="1" colspan="1">0.55(0.72)</td><td align="center" rowspan="1" colspan="1">1.15(1.02)</td><td align="center" rowspan="1" colspan="1">0.009</td><td align="center" rowspan="1" colspan="1">1.05</td><td align="center" rowspan="1" colspan="1">0.27</td><td align="center" rowspan="1" colspan="1">0.008</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="4" align="center" rowspan="1"> CAD-T (n= 12) </td><td colspan="4" align="center" rowspan="1"> CAD-C (n= 10) </td><td colspan="2" rowspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Height (cm)</td><td align="center" rowspan="1" colspan="1">167(12.2) </td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">171(10.5) </td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1"> Weight (kg) </td><td align="center" rowspan="1" colspan="1">82(23.7)</td><td align="center" rowspan="1" colspan="1">79(26.0)</td><td align="center" rowspan="1" colspan="1">0.03 </td><td align="center" rowspan="1" colspan="1">0.28 </td><td align="center" rowspan="1" colspan="1">86.5(16.4)</td><td align="left" rowspan="1" colspan="1">85.5(15.5)</td><td align="center" rowspan="1" colspan="1">0.93 </td><td align="center" rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">0.82</td><td align="center" rowspan="1" colspan="1">0.65</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m2)</td><td align="center" rowspan="1" colspan="1">29.0(5.7)</td><td align="center" rowspan="1" colspan="1">29.3(4.9)</td><td align="center" rowspan="1" colspan="1">0.04 </td><td align="center" rowspan="1" colspan="1">0.23 </td><td align="center" rowspan="1" colspan="1">27.9(4.1) </td><td align="center" rowspan="1" colspan="1">28.4(6.4)</td><td align="center" rowspan="1" colspan="1">0.49 </td><td align="center" rowspan="1" colspan="1">0.08 </td><td align="center" rowspan="1" colspan="1">0.82</td><td align="center" rowspan="1" colspan="1">0.80 </td></tr><tr><td align="left" rowspan="1" colspan="1">SBP (mmHg)</td><td align="center" rowspan="1" colspan="1">130(10)</td><td align="center" rowspan="1" colspan="1">120(2.5)</td><td align="center" rowspan="1" colspan="1">0.005</td><td align="center" rowspan="1" colspan="1">0.86</td><td align="center" rowspan="1" colspan="1">130(23.7)</td><td align="center" rowspan="1" colspan="1">140(17.5)</td><td align="center" rowspan="1" colspan="1">0.03</td><td align="center" rowspan="1" colspan="1">0.40</td><td align="center" rowspan="1" colspan="1">0.34</td><td align="center" rowspan="1" colspan="1">0.14</td></tr><tr><td align="left" rowspan="1" colspan="1">DBP (mmHg) </td><td align="center" rowspan="1" colspan="1">90(10)</td><td align="center" rowspan="1" colspan="1">80(2.5)</td><td align="center" rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">1.09</td><td align="center" rowspan="1" colspan="1">85(10)</td><td align="center" rowspan="1" colspan="1">90(10)</td><td align="center" rowspan="1" colspan="1">0.42</td><td align="center" rowspan="1" colspan="1">0.22</td><td align="center" rowspan="1" colspan="1">0.49</td><td align="center" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1"> HR (bpm) </td><td align="center" rowspan="1" colspan="1">63(13)</td><td align="center" rowspan="1" colspan="1">72(12)</td><td align="center" rowspan="1" colspan="1">0.15</td><td align="center" rowspan="1" colspan="1">0.52</td><td align="center" rowspan="1" colspan="1">60(9)</td><td align="center" rowspan="1" colspan="1">57(6)</td><td align="center" rowspan="1" colspan="1">0.06</td><td align="center" rowspan="1" colspan="1">0.24</td><td align="center" rowspan="1" colspan="1">0.45</td><td align="center" rowspan="1" colspan="1">0.97</td></tr><tr><td colspan="11" align="left" rowspan="1">Spectral and symbolic indices</td></tr><tr><td align="left" rowspan="1" colspan="1">LF (nu)</td><td align="center" rowspan="1" colspan="1">0.61(0.31)</td><td align="center" rowspan="1" colspan="1">0.58(0.13)</td><td align="center" rowspan="1" colspan="1">0.23</td><td align="center" rowspan="1" colspan="1">0.35</td><td align="center" rowspan="1" colspan="1">0.60(0.22)</td><td align="center" rowspan="1" colspan="1">0.55(0.21)</td><td align="center" rowspan="1" colspan="1">0.28</td><td align="center" rowspan="1" colspan="1">0.24</td><td align="center" rowspan="1" colspan="1">0.45</td><td align="center" rowspan="1" colspan="1">0.87</td></tr><tr><td align="left" rowspan="1" colspan="1">HF (nu)</td><td align="center" rowspan="1" colspan="1">0.38(0.31)</td><td align="center" rowspan="1" colspan="1">0.41(0.13)</td><td align="center" rowspan="1" colspan="1">0.23</td><td align="center" rowspan="1" colspan="1">0.35</td><td align="center" rowspan="1" colspan="1">0.39(0.22)</td><td align="center" rowspan="1" colspan="1">0.44(0.21)</td><td align="center" rowspan="1" colspan="1">0.28</td><td align="center" rowspan="1" colspan="1">0.24</td><td align="center" rowspan="1" colspan="1">0.45</td><td align="center" rowspan="1" colspan="1">0.87</td></tr><tr><td align="left" rowspan="1" colspan="1">0V%</td><td align="center" rowspan="1" colspan="1">35.7(29.6)</td><td align="center" rowspan="1" colspan="1">25.9(13.5)</td><td align="center" rowspan="1" colspan="1">0.09</td><td align="center" rowspan="1" colspan="1">0.50</td><td align="center" rowspan="1" colspan="1">22.5(14.2)</td><td align="center" rowspan="1" colspan="1">25.4(17.1)</td><td align="center" rowspan="1" colspan="1">0.07</td><td align="center" rowspan="1" colspan="1">0.61</td><td align="center" rowspan="1" colspan="1">0.10</td><td align="center" rowspan="1" colspan="1">0.82</td></tr><tr><td align="left" rowspan="1" colspan="1">2UV%</td><td align="center" rowspan="1" colspan="1">12.5(9.7)</td><td align="center" rowspan="1" colspan="1">19.0(13.0)</td><td align="center" rowspan="1" colspan="1">0.004</td><td align="center" rowspan="1" colspan="1">0.71</td><td align="center" rowspan="1" colspan="1">21.2(27.1)</td><td align="center" rowspan="1" colspan="1">16.2(13.1)</td><td align="center" rowspan="1" colspan="1">0.05</td><td align="center" rowspan="1" colspan="1">0.58</td><td align="center" rowspan="1" colspan="1">0.10</td><td align="center" rowspan="1" colspan="1">0.67</td></tr><tr><td colspan="11" align="left" rowspan="1">Inflammatory marker</td></tr><tr><td align="left" rowspan="1" colspan="1">hs-CRP (mg/dL)</td><td align="center" rowspan="1" colspan="1">1.2(1.1)</td><td align="center" rowspan="1" colspan="1">0.7(0.6)</td><td align="center" rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">0.63</td><td align="center" rowspan="1" colspan="1">0.9(0.5)</td><td align="center" rowspan="1" colspan="1">1.1(0.4)</td><td align="center" rowspan="1" colspan="1">0.006</td><td align="center" rowspan="1" colspan="1">0.43</td><td align="center" rowspan="1" colspan="1">0.18</td><td align="center" rowspan="1" colspan="1">0.22</td></tr></tbody></table><table-wrap-foot><fn id="TFN02"><p>Data are presented as median (interquartile range). RF-T = risk
factor-trained; CAD-T = coronary artery disease-trained; RF-C = risk
factor-control; CAD-C = coronary artery disease-control; ES= effect size;
BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood
pressure; HR = heart rate at rest; LF= low frequency; HF= high frequency;
nu= normalized units; 0V% = percentage of pattern with no variation; 2UV% =
percentage of pattern with two unlike variations; hs-CRP = high-sensitivity
C-reactive protein. Signi&#x0fb01;cance level of p&#x0003c;0.02.</p></fn></table-wrap-foot></table-wrap>
</p><p>At baseline, there were no significant differences in HRV indices (0V% and 2UV%; LFnu
and HFnu) between trained and control groups. In the RF-T group, only 0V% (sympathetic
modulation) values decreased after IT (p&#x0003c;0.02), while in the CAD-T group, LFnu and
0V% did not differ significantly at baseline (p&#x0003e;0.02). For both trained groups, 0V%
presented medium ES. Moreover, only the RF-T group presented higher LFnu and 0UV% values
than the RF-C group (p=0.01).</p><p>Regarding parasympathetic modulation, only 2UV% values increased significantly in the
RF-T and CAD-T groups (p&#x0003c;0.02) after IT. For both trained group, 2UV% presented
medium ES. Moreover, the RF-T group presented higher HFnu and 2UV% values than the RF-C
group (p&#x0003c;0.02), while the HFnu and 2UV% values of the CAD-T and CAD-C groups did not
differ significantly (p&#x0003e;0.02). None of the HRV indices in the control groups showed
any significant changes after 16 weeks.</p><p>There were no significant differences among groups in hs-CRP level at baseline. After
IT, the hs-CRP level in the RF-T and CAD-T groups diminished significantly (p&#x0003c;0.02),
while in both control groups increased significantly (p&#x0003c;0.02). For the RF-T group,
hs-CRP presented small ES, while in the CAD-T group, the ES was medium. Furthermore, the
levels of hs-CRP (p=0.008) in the RF-T group were lower than those observed in the RF-C
group.</p><sec><title>Analysis of covariance (ANCOVA) and linear regression</title><p>The linear regression examined the association of the use of medication and risk
factors with the hs CRP levels and only symbolic indices. Use of beta-blockers
accounted for 51% of the variance in 0V% in the RF-T group (p&#x0003c;0.05). In the CAD-T
group, however, the use of beta-blockers and angiotensin-converting enzyme (ACE)
inhibitors, dyslipidemia, and hypertension accounted for 65% of the variance in 0V%
(p&#x0003c;0.05). Furthermore, the use of beta-blockers and ACE inhibitors as well as
dyslipidemia accounted for 62% of the variance in 2UV% in the CAD-T group
(p&#x0003c;0.05). The covariates that accounted for 50% of the variance in hs-CRP levels
included PCI&#x0003e;3 months, use of ACE inhibitors, hypolipidemic agents, and
dyslipidemia in the CAD-T group (p&#x0003c;0.05).</p><p>In the RF-C group, the use of beta-blockers, hypertension and obesity explained 69%
of the variance in 2UV% (p&#x0003c;0.05). In the CAD-C group, dyslipidemia, hypertension,
and obesity explained 64% of the variance in 0V% (p&#x0003c;0.05). All of the models
satisfied the hypotheses of homoscedasticity and normality of residuals (<xref ref-type="table" rid="t03">Table 3</xref>). </p><p>
<table-wrap id="t03" orientation="portrait" position="float"><label>Table 3.</label><caption><title>Analysis of covariance (ANCOVA) and linear regression analysis of HRV
indices and hs-CRP and the covariates for the trained and control
groups.</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">
<bold>Groups</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>Dependent variables</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>Covariates</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>P</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>Intercept</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>Estimate</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>r<sup>2</sup></bold>
</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">FT-T</td><td align="center" rowspan="1" colspan="1">0V%</td><td align="center" rowspan="1" colspan="1">Beta blocker</td><td align="center" rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">28.96</td><td align="center" rowspan="1" colspan="1">-14.69</td><td align="center" rowspan="1" colspan="1">0.51</td></tr><tr><td rowspan="10" align="center" colspan="1">CAD-T </td><td rowspan="4" align="center" colspan="1">0V%</td><td align="center" rowspan="1" colspan="1">Beta blocker</td><td align="center" rowspan="1" colspan="1">0.05</td><td rowspan="4" align="center" colspan="1">38.03</td><td align="center" rowspan="1" colspan="1">-17.43</td><td rowspan="4" align="center" colspan="1">0.65</td></tr><tr><td align="center" rowspan="1" colspan="1">ACE inhibitor</td><td align="center" rowspan="1" colspan="1">0.03</td><td align="center" rowspan="1" colspan="1">-12.78</td></tr><tr><td align="center" rowspan="1" colspan="1">Dyslipidemia</td><td align="center" rowspan="1" colspan="1">0.005</td><td align="center" rowspan="1" colspan="1">10.14</td></tr><tr><td align="center" rowspan="1" colspan="1">Hypertension </td><td align="center" rowspan="1" colspan="1">0.01 </td><td align="center" rowspan="1" colspan="1">18.41</td></tr><tr><td rowspan="3" align="center" colspan="1">2UV%</td><td align="center" rowspan="1" colspan="1">Beta blocker</td><td align="center" rowspan="1" colspan="1">0.02</td><td rowspan="3" align="center" colspan="1">9.78</td><td align="center" rowspan="1" colspan="1">10.74</td><td rowspan="3" align="center" colspan="1">0.62</td></tr><tr><td align="center" rowspan="1" colspan="1">ACE inhibitor </td><td align="center" rowspan="1" colspan="1">0.05</td><td align="center" rowspan="1" colspan="1">11.22</td></tr><tr><td align="center" rowspan="1" colspan="1">Dyslipidemia</td><td align="center" rowspan="1" colspan="1">0.007</td><td align="center" rowspan="1" colspan="1">-5.65</td></tr><tr><td rowspan="3" align="center" colspan="1">hs-CRP</td><td align="center" rowspan="1" colspan="1">ACE inhibitor</td><td align="center" rowspan="1" colspan="1">0.04</td><td rowspan="3" align="center" colspan="1">1.17</td><td align="center" rowspan="1" colspan="1">-9.25</td><td rowspan="3" align="center" colspan="1">0.50</td></tr><tr><td align="center" rowspan="1" colspan="1">Hypolipidemic </td><td align="center" rowspan="1" colspan="1">0.03</td><td align="center" rowspan="1" colspan="1">-0.18</td></tr><tr><td align="center" rowspan="1" colspan="1">PCI</td><td align="center" rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">-0.20</td></tr><tr><td rowspan="3" align="left" colspan="1">RF-C </td><td rowspan="3" align="center" colspan="1">2UV%</td><td align="center" rowspan="1" colspan="1">Beta blocker</td><td align="center" rowspan="1" colspan="1">0.04</td><td rowspan="3" align="center" colspan="1">48.07</td><td align="center" rowspan="1" colspan="1">-3.41</td><td rowspan="3" align="center" colspan="1">0.69</td></tr><tr><td align="center" rowspan="1" colspan="1">Hypertension</td><td align="center" rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">3.20</td></tr><tr><td align="center" rowspan="1" colspan="1">Obesity</td><td align="center" rowspan="1" colspan="1">0.05</td><td align="center" rowspan="1" colspan="1">3.15</td></tr><tr><td rowspan="3" align="left" colspan="1">CAD-C</td><td rowspan="3" align="center" colspan="1">0V%</td><td align="center" rowspan="1" colspan="1">Dyslipidemia</td><td align="center" rowspan="1" colspan="1">0.02</td><td rowspan="3" align="center" colspan="1">48.24</td><td align="center" rowspan="1" colspan="1">20.41</td><td rowspan="3" align="center" colspan="1">0.64</td></tr><tr><td align="center" rowspan="1" colspan="1">Hypertension</td><td align="center" rowspan="1" colspan="1">0.03</td><td align="center" rowspan="1" colspan="1">11.84</td></tr><tr><td align="center" rowspan="1" colspan="1">Obesity</td><td align="center" rowspan="1" colspan="1">0.04</td><td align="center" rowspan="1" colspan="1">0.85</td></tr></tbody></table><table-wrap-foot><fn id="TFN03"><p>r<sup>2</sup> = coefficient of determination; 0V% = percentage of pattern
with no variation; 2UV% = percentage of pattern with two unlike
variations; hs-CRP = high-sensitivity C-reactive protein; ACE =
angiotensin-converting enzyme; RF-T = risk factor-trained; CAD-T =
coronary artery disease-trained; RF-C = risk factor-control; CAD-C =
coronary artery disease-control; PCI = percutaneous coronary
intervention; ANCOVA and linear regression. Signi&#x0fb01;cance level of
p&#x0003c;0.05.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec><title>Correlation between heart rate variability indices and C-reactive protein</title><p>A significant and positive correlation was found between 0V% (sympathetic modulation)
and hs-CRP before (CAD-T, r=0.78; RF-T, r=0.85, with p&#x0003c;0.001) and after IT (CAD-T,
r=0.80; RF-T, r=0.97, with p&#x0003c;0.001). With regard to 2UV% (parasympathetic
modulation), a significantly relevant correlation was found with hs-CRP before
(CAD-T, r=-0.74; RF-T, r=-0.78, with p&#x0003c;0.001) and after IT (CAD-T, r=-0.75; RF-T,
r=-0.86, with p&#x0003c;0.001). Spectral indices did not correlate with hs-CRP
(p&#x0003e;0.05).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>This study demonstrated that IT based on VAT led to significant improvements in the
autonomic modulation of HR as well as a reduction in hs-CRP levels. Furthermore, the
present study showed that hs-CRP levels are positively associated with sympathetic
modulation and negatively associated with parasympathetic modulation.</p><p>Notably, IT at the VAT level promoted an increase in parasympathetic modulation in both
groups RF-T and CAD-T, while the reduction in sympathetic modulation was observed only
for the RF-T group. Previous studies have shown that autonomic adaptions can be
attributed to a reduction in efferent sympathetic neural outflow to the sinoatrial
node<xref rid="B22" ref-type="bibr">22</xref>
<sup>,</sup>
<xref rid="B23" ref-type="bibr">23</xref>. Other mechanisms that result in an increase
in vagal modulation through exercise training include the shear stress-induced up
regulation of endothelial nitric oxide (NO) synthase. Recent research has demonstrated
that nitric oxide, which is widely recognized as an endothelial control mechanism, is
also a vagal modulator. In addition, NO exerts a facilitative effect on the afferent
baroreflex and augments central and peripheral vagal neuronal activity<xref rid="B24" ref-type="bibr">24</xref>. Regarding methodological aspects of HRV
analysis, although the symbolic analysis was more efficient in identifying changes in
cardiac autonomic control than spectral analysis, this method combined with standard
linear parameters can improve the performance of HRV analysis. Moreover, this finding
was important for determining the applicability of symbolic analysis as a tool to
evaluate autonomic adaptation-induced exercise training.</p><p>A significant decrease in CRP levels was observed in both trained groups. Particularly
in the RF-T group, the decreases in the hs-CRP level indicated a reduced CAD risk after
IT. The CAD-T group showed a greater reduction in the hs-CRP level than the RF-T group,
which may suggest that high-risk individuals benefit more from IT than those with lower
risk. In fact, this finding is consistent with previous observations showing that
individuals with a high level of physical performance demonstrate lower hs-CRP levels
than individuals with a sedentary lifestyle, regardless of gender and associated risk
factors<xref rid="B25" ref-type="bibr">25</xref>.</p><p>Recent studies have shown that increased parasympathetic modulation may also play a role
in mediating the inhibition of the inflammatory response observed in trained
individuals<xref rid="B26" ref-type="bibr">26</xref>
<sup>-</sup>
<xref rid="B28" ref-type="bibr">28</xref>. The authors of these studies believe that one
of the alternative mechanisms leading to reduced levels of circulating pro-inflammatory
cytokines involves the cholinergic anti-inflammatory pathway<xref rid="B04" ref-type="bibr">4</xref>. In this pathway, acetylcholine inhibits the synthesis and release
of pro-inflammatory cytokines by macrophages and other cytokine-producing cells by
activating the alpha-7 nicotinic receptor (nAChR&#x003b1;7), which is expressed at the plasma
membrane of these immune cells, resulting in reduced CRP levels<xref rid="B04" ref-type="bibr">4</xref>.</p><p>Singh et al.<xref rid="B29" ref-type="bibr">29</xref> found a correlation between the
linear indices of HRV, which reflect sympathetic modulation, and hs-CRP. These authors
suggest that sympathetic activation promotes an increased concentration of circulating
catecholamines, thereby stimulating the synthesis and release of pro-inflammatory
cytokines. The adaptation of the sympathetic autonomic modulation of HR in the RF-T
group, as shown by the reduced 0V% after IT, may also be considered an important pathway
contributing to reduce CRP levels.</p><p>Analysis of the correlation between HRV indices and hs-CRP levels, adjusted according to
clinical variables (angioplasty&#x0003e;3 months), the use of medications (beta-blockers, ACE
inhibitor, and hypolipidemic agents), and cardiovascular risk factors (hypertension,
dyslipidemia, and obesity), indicated that the decrease in hs-CRP levels after IT was
negatively correlated with the 2UV% (which reflects the parasympathetic modulation of
HR) and positively correlated with the 0V% (which reflects the sympathetic modulation of
HR). These findings reinforce the notion of a cholinergic anti-inflammatory pathway, and
the anti inflammatory properties of acetylcholine, and suggest that vagal modulation may
inhibit the production of pro inflammatory mediators, and thus establishing the
causality link between both measures.</p><p>With regard to BP, both trained groups presented a decrease in systolic and diastolic BP
at rest after IT. Several mechanisms may be involved in the reduction in BP, such as
decreased sympathetic tone in smooth muscle cells in the arterial wall and possible
increase in NO bioavailability that decreases peripheral vascular resistance<xref rid="B24" ref-type="bibr">24</xref>
<sup>,</sup>
<xref rid="B30" ref-type="bibr">30</xref>.</p><p>It is noteworthy that the RF and CAD groups are different in relation to presence of
risk factors and medication use. The same can be observed between the trained and
control RF groups. Considering that cardiovascular risk factors and medication may
affect the HRV and the hs-CRP, analysis of covariance and linear regression showed that
cardiovascular risk factors, such as dyslipidemia, hypertension, and obesity, led to a
significant negative effect on 0V% (sympathetic modulation) and on 2UV% (parasympathetic
modulation) in the trained and control groups. Therefore, IT represents an important
non-pharmacological therapeutic approach that should be included in the cardiac
rehabilitation program of patients with CAD in view of its benefits in reducing risk
factors and preventing the progression of CAD. On the other hand, medications such as
beta-blockers and ACE inhibitors can attenuate vasoconstriction and sympathetic
modulation, improving autonomic modulation of HR<xref rid="B31" ref-type="bibr">31</xref>. Hypolipidemic agents and ACE inhibitors have beneficial effects on hs-CRP
because these drugs act on the control of lipid profile and hypertension, which are
important risk factors to the development of atherosclerosis<xref rid="B32" ref-type="bibr">32</xref>.</p><p>The results of the present study may offer new possibilities in the field of cardiac
rehabilitation, with respect to exercise training programs at VAT level.
Cardiorespiratory parameters obtained at the VAT are of fundamental clinical importance
to diagnosis, prescription of physical exercise, evaluation and re-evaluation of
functional aerobic capacity, and monitoring of patients' development during exercise
training programs. Furthermore, these results provide new insight into the main effects
of IT on cardiac autonomic modulation and inflammation that could be expected in a
larger sample. Thus, we can further develop the IT program based on VAT intensities as a
new treatment protocol for cardiac patients.</p><sec><title>Study limitations</title><p>The autonomic adaptations promoted by the IT program are restricted to male patients
with CAD and/or cardiovascular RF, which prevents us from generalizing these results
to women and other cardiac diseases. Other limitations were the small sample and the
fact that the present study did not include a group of healthy male subjects. The
latter is especially important considering that the symbolic indices and hs-CRP
present high inter-individual variability. Moreover, other inflammatory markers such
as interleukin 6, fibrinogen, soluble intercellular adhesion molecule-1, and serum
amyloid A, as well as echocardiogram were not measured. Furthermore, the CPET in
cardiac rehabilitation centers still remains inaccessible, mainly due to the
complexity and high costs of this technology. However, considering its importance,
strong efforts are needed to encourage the use of CPET in exercise intensity
assessment and prescription of cardiac rehabilitation programs.</p></sec></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Interval training program based on VAT level led to improve in cardiac autonomic
modulation, evidenced by increase in the parasympathetic modulation and decrease in the
sympathetic modulation, associated with reduction of hs-CRP.</p></sec></body><back><ack><title>Acknowledgements</title><p>This research was supported by Conselho Nacional de Desenvolvimento Cient&#x000ed;fico e
Tecnol&#x000f3;gico (CNPq), Brazil [grant numbers 478601/2010-7, 308348/2009-5 and
131594/2011-7]. We wish to thank Alberto Porta, PhD, for providing the program for
symbolic analysis.</p></ack><fn-group><fn fn-type="other"><p>
<list list-type="bullet"><title>BULLET POINTS</title><list-item><p>Autonomic dysfunction and inflammation are present in coronary artery
disease.</p></list-item><list-item><p>Interval training (IT) is a new protocol applied to cardiac
rehabilitation.</p></list-item><list-item><p>Ventilatory anaerobic threshold is a good parameter to prescribe exercise
intensity.</p></list-item><list-item><p>Parasympathetic modulation can be related to a reduction in inflammation
after IT.</p></list-item><list-item><p>These findings reinforce the anti-inflammatory effects of exercise.</p></list-item></list>
</p></fn></fn-group><ref-list><title>References </title><ref id="B01"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von K&#x000e4;nel</surname><given-names>R</given-names></name><name><surname>Carney</surname><given-names>RM</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Whooley</surname><given-names>MA</given-names></name></person-group><article-title>Heart rate variability and biomarkers of systemic inflammation in
patients with stable coronary heart disease: findings from the Heart and Soul
Study</article-title><source>Clin Res Cardiol</source><year>2011</year><volume>100</volume><issue>3</issue><fpage>241</fpage><lpage>247</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00392-010-0236-5">http://dx.doi.org/10.1007/s00392-010-0236-5</ext-link><pub-id pub-id-type="pmid">20857123</pub-id></element-citation></ref><ref id="B02"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ta&#x000e7;oy</surname><given-names>G</given-names></name><name><surname>A&#x000e7;ikg&#x000f6;z</surname><given-names>K</given-names></name><name><surname>Kocaman</surname><given-names>SA</given-names></name><name><surname>Ozdemir</surname><given-names>M</given-names></name><name><surname>Cengel</surname><given-names>A</given-names></name></person-group><article-title>Is there a relationship between obesity, heart rate variability and
inflammatory parameters in heart failure?</article-title><source>J Cardiovasc Med (Hagerstown)</source><year>2010</year><volume>11</volume><issue>2</issue><fpage>118</fpage><lpage>124</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2459/JCM.0b013e328332e730">http://dx.doi.org/10.2459/JCM.0b013e328332e730</ext-link><pub-id pub-id-type="pmid">19809354</pub-id></element-citation></ref><ref id="B03"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haensel</surname><given-names>A</given-names></name><name><surname>Mills</surname><given-names>PJ</given-names></name><name><surname>Nelesen</surname><given-names>RA</given-names></name><name><surname>Ziegler</surname><given-names>MG</given-names></name><name><surname>Dimsdale</surname><given-names>JE</given-names></name></person-group><article-title>The relationship between heart rate variability and inflammatory
markers in cardiovascular diseases</article-title><source>Psychoneuroendocrinology</source><year>2008</year><volume>33</volume><issue>10</issue><fpage>1305</fpage><lpage>1312</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.psyneuen.2008.08.007">http://dx.doi.org/10.1016/j.psyneuen.2008.08.007</ext-link><pub-id pub-id-type="pmid">18819754</pub-id></element-citation></ref><ref id="B04"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tracey</surname><given-names>KJ</given-names></name></person-group><article-title>The inflammatory reflex</article-title><source>Nature</source><year>2002</year><volume>420</volume><issue>6917</issue><fpage>853</fpage><lpage>859</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature01321">
http://dx.doi.org/10.1038/nature01321</ext-link><pub-id pub-id-type="pmid">12490958</pub-id></element-citation></ref><ref id="B05"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nolan</surname><given-names>RP</given-names></name><name><surname>Jong</surname><given-names>P</given-names></name><name><surname>Barry-Bianchi</surname><given-names>SM</given-names></name><name><surname>Tanaka</surname><given-names>TH</given-names></name><name><surname>Floras</surname><given-names>JS</given-names></name></person-group><article-title>Effects of drug, biobehavioral and exercise therapies on heart rate
variability in coronary artery disease: a systematic review</article-title><source>Eur J Cardiovasc Prev Rehabil</source><year>2008</year><volume>15</volume><issue>4</issue><fpage>386</fpage><lpage>396</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/HJR.0b013e3283030a97">http://dx.doi.org/10.1097/HJR.0b013e3283030a97</ext-link><pub-id pub-id-type="pmid">18677161</pub-id></element-citation></ref><ref id="B06"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cornish</surname><given-names>AK</given-names></name><name><surname>Broadbent</surname><given-names>S</given-names></name><name><surname>Cheema</surname><given-names>BS</given-names></name></person-group><article-title>Interval training for patients with coronary artery disease: a
systematic review</article-title><source>Eur J Appl Physiol</source><year>2011</year><volume>111</volume><issue>4</issue><fpage>579</fpage><lpage>589</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00421-010-1682-5">http://dx.doi.org/10.1007/s00421-010-1682-5</ext-link><pub-id pub-id-type="pmid">20972578</pub-id></element-citation></ref><ref id="B07"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Currie</surname><given-names>KD</given-names></name><name><surname>Rosen</surname><given-names>LM</given-names></name><name><surname>Millar</surname><given-names>PJ</given-names></name><name><surname>McKelvie</surname><given-names>RS</given-names></name><name><surname>Macdonald</surname><given-names>MJ</given-names></name></person-group><article-title>Heart rate recovery and heart rate variability are unchanged in
patients with coronary artery disease following 12 weeks of high-intensity
interval and moderate-intensity endurance exercise training</article-title><source>Appl Physiol Nutr Metab</source><year>2013</year><volume>38</volume><issue>6</issue><fpage>644</fpage><lpage>650</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1139/apnm-2012-0354">http://dx.doi.org/10.1139/apnm-2012-0354</ext-link><pub-id pub-id-type="pmid">23724882</pub-id></element-citation></ref><ref id="B08"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warburton</surname><given-names>DE</given-names></name><name><surname>McKenzie</surname><given-names>DC</given-names></name><name><surname>Haykowsky</surname><given-names>MJ</given-names></name><name><surname>Taylor</surname><given-names>A</given-names></name><name><surname>Shoemaker</surname><given-names>P</given-names></name><name><surname>Ignaszewski</surname><given-names>AP</given-names></name></person-group><article-title>Effectiveness of high-intensity interval training for the
rehabilitation of patients with coronary artery disease</article-title><source>Am J Cardiol</source><year>2005</year><volume>95</volume><issue>9</issue><fpage>1080</fpage><lpage>1084</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.amjcard.2004.12.063">http://dx.doi.org/10.1016/j.amjcard.2004.12.063</ext-link><pub-id pub-id-type="pmid">15842976</pub-id></element-citation></ref><ref id="B09"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Currie</surname><given-names>KD</given-names></name><name><surname>Dubberley</surname><given-names>JB</given-names></name><name><surname>McKelvie</surname><given-names>RS</given-names></name><name><surname>MacDonald</surname><given-names>MJ</given-names></name></person-group><article-title>Low-volume, high-intensity interval training in patients with
CAD</article-title><source>Med Sci Sports Exerc</source><year>2013</year><volume>45</volume><issue>8</issue><fpage>1436</fpage><lpage>1442</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1249/MSS.0b013e31828bbbd4">http://dx.doi.org/10.1249/MSS.0b013e31828bbbd4</ext-link><pub-id pub-id-type="pmid">23470301</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munk</surname><given-names>PS</given-names></name><name><surname>Butt</surname><given-names>N</given-names></name><name><surname>Larsen</surname><given-names>AI</given-names></name></person-group><article-title>High-intensity interval exercise training improves heart rate
variability in patients following percutaneous coronary intervention for angina
pectoris</article-title><source>Int J Cardiol</source><year>2010</year><volume>145</volume><issue>2</issue><fpage>312</fpage><lpage>314</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ijcard.2009.11.015">http://dx.doi.org/10.1016/j.ijcard.2009.11.015</ext-link><pub-id pub-id-type="pmid">19962772</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gamelin</surname><given-names>FX</given-names></name><name><surname>Berthoin</surname><given-names>S</given-names></name><name><surname>Bosquet</surname><given-names>L</given-names></name></person-group><article-title>Validity of the polar S810 heart rate monitor to measure R-R intervals
at rest</article-title><source>Med Sci Sports Exerc</source><year>2006</year><volume>38</volume><issue>5</issue><fpage>887</fpage><lpage>893</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1249/01.mss.0000218135.79476.9c">http://dx.doi.org/10.1249/01.mss.0000218135.79476.9c</ext-link><pub-id pub-id-type="pmid">16672842</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malliani</surname><given-names>A</given-names></name><name><surname>Pagani</surname><given-names>M</given-names></name><name><surname>Lombardi</surname><given-names>F</given-names></name><name><surname>Cerutti</surname><given-names>S</given-names></name></person-group><article-title>Cardiovascular neural regulation explored in the frequency
domain</article-title><source>Circulation</source><year>1991</year><volume>84</volume><issue>2</issue><fpage>482</fpage><lpage>492</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/01.CIR.84.2.482">http://dx.doi.org/10.1161/01.CIR.84.2.482</ext-link><pub-id pub-id-type="pmid">1860193</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porta</surname><given-names>A</given-names></name><name><surname>Guzzetti</surname><given-names>S</given-names></name><name><surname>Montano</surname><given-names>N</given-names></name><name><surname>Furlan</surname><given-names>R</given-names></name><name><surname>Pagani</surname><given-names>M</given-names></name><name><surname>Malliani</surname><given-names>A</given-names></name></person-group><article-title>Entropy, entropy rate, and pattern classification as tools to typify
complexity in short heart period variability series</article-title><source>IEEE Trans Biomed Eng</source><year>2001</year><volume>48</volume><issue>11</issue><fpage>1282</fpage><lpage>1291</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1109/10.959324">http://dx.doi.org/10.1109/10.959324</ext-link><pub-id pub-id-type="pmid">11686627</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wasserman</surname><given-names>K</given-names></name><name><surname>Hansen</surname><given-names>JE</given-names></name><name><surname>Sue</surname><given-names>D</given-names></name><name><surname>Whipp</surname><given-names>BJ</given-names></name><name><surname>Casaburi</surname><given-names>R</given-names></name></person-group><source>Principles of exercise testing and interpretation</source><edition> 4th </edition><publisher-loc>Philadelphia</publisher-loc><publisher-name>Williams and Wilkins</publisher-name><year>1999</year></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fletcher</surname><given-names>GF</given-names></name><name><surname>Balady</surname><given-names>GJ</given-names></name><name><surname>Amsterdam</surname><given-names>EA</given-names></name><name><surname>Chaitman</surname><given-names>B</given-names></name><name><surname>Eckel</surname><given-names>R</given-names></name><name><surname>Fleg</surname><given-names>J</given-names></name></person-group><article-title>Exercise standards for testing and training: a statement for
healthcare professionals from the American Heart Association</article-title><source>Circulation</source><year>2001</year><volume>104</volume><issue>14</issue><fpage>1694</fpage><lpage>1740</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/hc3901.095960">http://dx.doi.org/10.1161/hc3901.095960</ext-link><pub-id pub-id-type="pmid">11581152</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zamun&#x000e9;r</surname><given-names>AR</given-names></name><name><surname>Catai</surname><given-names>AM</given-names></name><name><surname>Martins</surname><given-names>LE</given-names></name><name><surname>Sakabe</surname><given-names>DI</given-names></name><name><surname>Da Silva</surname><given-names>E</given-names></name></person-group><article-title>Identification and agreement of first turn point by mathematical
analysis applied to heart rate, carbon dioxide output and
electromyography</article-title><source>Braz J Phys Ther</source><year>2013</year><volume>17</volume><issue>6</issue><fpage>614</fpage><lpage>622</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1590/S1413-35552012005000129">http://dx.doi.org/10.1590/S1413-35552012005000129</ext-link><pub-id pub-id-type="pmid">24346296</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higa</surname><given-names>MN</given-names></name><name><surname>Silva</surname><given-names>E</given-names></name><name><surname>Neves</surname><given-names>VF</given-names></name><name><surname>Catai</surname><given-names>AM</given-names></name><name><surname>Gallo</surname><given-names>L Jr</given-names></name><name><surname>Silva de S&#x000e1;</surname><given-names>MF</given-names></name></person-group><article-title>Comparison of anaerobic threshold determined by visual and
mathematical methods in healthy women</article-title><source>Braz J Med Biol Res</source><year>2007</year><volume>40</volume><issue>4</issue><fpage>501</fpage><lpage>508</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1590/S0100-879X2007000400008">http://dx.doi.org/10.1590/S0100-879X2007000400008</ext-link><pub-id pub-id-type="pmid">17401493</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sirol</surname><given-names>FN</given-names></name><name><surname>Sakabe</surname><given-names>DI</given-names></name><name><surname>Catai</surname><given-names>AM</given-names></name><name><surname>Milan</surname><given-names>LA</given-names></name><name><surname>Martins</surname><given-names>LEB</given-names></name><name><surname>Silva</surname><given-names>E</given-names></name></person-group><article-title>Compara&#x000e7;&#x000e3;o dos n&#x000ed;veis de potencia e da frequ&#x000ea;ncia card&#x000ed;aca no limiar
de anaerobiose determinado por dois m&#x000e9;todos indiretos</article-title><source>Rev Bras Fisioter</source><year>2005</year><volume>9</volume><issue>2</issue><fpage>7</fpage><lpage>7</lpage></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pithon</surname><given-names>KR</given-names></name><name><surname>Martins</surname><given-names>LEB</given-names></name><name><surname>Gallo</surname><given-names>L Jr</given-names></name><name><surname>Catai</surname><given-names>AM</given-names></name><name><surname>Silva</surname><given-names>E</given-names></name></person-group><article-title>Compara&#x000e7;&#x000e3;o das respostas cardiorrespirat&#x000f3;rias entre exerc&#x000ed;cio de carga
constante e incremental abaixo, acima e no limiar de anaerobiose
ventilat&#x000f3;rio</article-title><source>Rev Bras Fisioter</source><year>2006</year><volume>10</volume><issue>2</issue><fpage>163</fpage><lpage>169</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1590/S1413-35552006000200005">http://dx.doi.org/10.1590/S1413-35552006000200005</ext-link></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lara Fernandes</surname><given-names>J</given-names></name><name><surname>Serrano</surname><given-names>CV Jr</given-names></name><name><surname>Toledo</surname><given-names>F</given-names></name><name><surname>Hunziker</surname><given-names>MF</given-names></name><name><surname>Zamperini</surname><given-names>A</given-names></name><name><surname>Teo</surname><given-names>FH</given-names></name></person-group><article-title>Acute and chronic effects of exercise on inflammatory markers and
B-type natriuretic peptide in patients with coronary artery
disease</article-title><source>Clin Res Cardiol</source><year>2011</year><volume>100</volume><issue>1</issue><fpage>77</fpage><lpage>84</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00392-010-0215-x">http://dx.doi.org/10.1007/s00392-010-0215-x</ext-link><pub-id pub-id-type="pmid">20835904</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>J</given-names></name></person-group><source>Statistical power analysis for the behavioral sciences</source><publisher-loc>Ilinois</publisher-loc><publisher-name>Routledge</publisher-name><year>1988</year></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blomqvist</surname><given-names>CG</given-names></name><name><surname>Saltin</surname><given-names>B</given-names></name></person-group><article-title>Cardiovascular adaptations to physical training</article-title><source>Annu Rev Physiol</source><year>1983</year><volume>45</volume><issue>1</issue><fpage>169</fpage><lpage>189</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1146/annurev.ph.45.030183.001125">http://dx.doi.org/10.1146/annurev.ph.45.030183.001125</ext-link><pub-id pub-id-type="pmid">6221687</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dixon</surname><given-names>EM</given-names></name><name><surname>Kamath</surname><given-names>MV</given-names></name><name><surname>McCartney</surname><given-names>N</given-names></name><name><surname>Fallen</surname><given-names>EL</given-names></name></person-group><article-title>Neural regulation of heart rate variability in endurance athletes and
sedentary controls</article-title><source>Cardiovasc Res</source><year>1992</year><volume>26</volume><issue>7</issue><fpage>713</fpage><lpage>719</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/cvr/26.7.713">http://dx.doi.org/10.1093/cvr/26.7.713</ext-link><pub-id pub-id-type="pmid">1423437</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buch</surname><given-names>AN</given-names></name><name><surname>Coote</surname><given-names>JH</given-names></name><name><surname>Townend</surname><given-names>JN</given-names></name></person-group><article-title>Mortality, cardiac vagal control and physical training--what's the
link?</article-title><source>Exp Physiol</source><year>2002</year><volume>87</volume><issue>4</issue><fpage>423</fpage><lpage>435</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1469-445X.2002.tb00055.x">http://dx.doi.org/10.1111/j.1469-445X.2002.tb00055.x</ext-link><pub-id pub-id-type="pmid">12392106</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldhammer</surname><given-names>E</given-names></name><name><surname>Tanchilevitch</surname><given-names>A</given-names></name><name><surname>Maor</surname><given-names>I</given-names></name><name><surname>Beniamini</surname><given-names>Y</given-names></name><name><surname>Rosenschein</surname><given-names>U</given-names></name><name><surname>Sagiv</surname><given-names>M</given-names></name></person-group><article-title>Exercise training modulates cytokines activity in coronary heart
disease patients</article-title><source>Int J Cardiol</source><year>2005</year><volume>100</volume><issue>1</issue><fpage>93</fpage><lpage>99</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ijcard.2004.08.073">http://dx.doi.org/10.1016/j.ijcard.2004.08.073</ext-link><pub-id pub-id-type="pmid">15820291</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soares-Miranda</surname><given-names>L</given-names></name><name><surname>Negrao</surname><given-names>CE</given-names></name><name><surname>Antunes-Correa</surname><given-names>LM</given-names></name><name><surname>Nobre</surname><given-names>TS</given-names></name><name><surname>Silva</surname><given-names>P</given-names></name><name><surname>Santos</surname><given-names>R</given-names></name></person-group><article-title>High levels of C-reactive protein are associated with reduced vagal
modulation and low physical activity in young adults</article-title><source>Scand J Med Sci Sports</source><year>2012</year><volume>22</volume><issue>2</issue><fpage>278</fpage><lpage>284</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1600-0838.2010.01163.x">http://dx.doi.org/10.1111/j.1600-0838.2010.01163.x</ext-link><pub-id pub-id-type="pmid">20626701</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamer</surname><given-names>M</given-names></name><name><surname>Steptoe</surname><given-names>A</given-names></name></person-group><article-title>Association between physical fitness, parasympathetic control, and
proinflammatory responses to mental stress</article-title><source>Psychosom Med</source><year>2007</year><volume>69</volume><issue>7</issue><fpage>660</fpage><lpage>666</lpage><pub-id pub-id-type="pmid">17724255</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heffernan</surname><given-names>KS</given-names></name><name><surname>Jae</surname><given-names>SY</given-names></name><name><surname>Vieira</surname><given-names>VJ</given-names></name><name><surname>Iwamoto</surname><given-names>GA</given-names></name><name><surname>Wilund</surname><given-names>KR</given-names></name><name><surname>Woods</surname><given-names>JA</given-names></name></person-group><article-title>C-reactive protein and cardiac vagal activity following resistance
exercise training in young African-American and white men</article-title><source>Am J Physiol Regul Integr Comp Physiol</source><year>2009</year><volume>296</volume><issue>4</issue><fpage>R1098</fpage><lpage>R1105</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1152/ajpregu.90936.2008">http://dx.doi.org/10.1152/ajpregu.90936.2008</ext-link><pub-id pub-id-type="pmid">19193941</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>P</given-names></name><name><surname>Hawkley</surname><given-names>LC</given-names></name><name><surname>McDade</surname><given-names>TW</given-names></name><name><surname>Cacioppo</surname><given-names>JT</given-names></name><name><surname>Masi</surname><given-names>CM</given-names></name></person-group><article-title>Autonomic tone and C-reactive protein: a prospective population-based
study</article-title><source>Clin Auton Res</source><year>2009</year><volume>19</volume><issue>6</issue><fpage>367</fpage><lpage>374</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s10286-009-0019-0">http://dx.doi.org/10.1007/s10286-009-0019-0</ext-link><pub-id pub-id-type="pmid">19504232</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luk</surname><given-names>TH</given-names></name><name><surname>Dai</surname><given-names>YL</given-names></name><name><surname>Siu</surname><given-names>CW</given-names></name><name><surname>Yiu</surname><given-names>KH</given-names></name><name><surname>Chan</surname><given-names>HT</given-names></name><name><surname>Lee</surname><given-names>SW</given-names></name></person-group><article-title>Effect of exercise training on vascular endothelial function in
patients with stable coronary artery disease: a randomized controlled
trial</article-title><source>Eur J Prev Cardiol</source><year>2012</year><volume>19</volume><issue>4</issue><fpage>830</fpage><lpage>839</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1177/1741826711415679">http://dx.doi.org/10.1177/1741826711415679</ext-link><pub-id pub-id-type="pmid">21724681</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bilchick</surname><given-names>KC</given-names></name><name><surname>Berger</surname><given-names>RD</given-names></name></person-group><article-title>Heart rate variability</article-title><source>J Cardiovasc Electrophysiol</source><year>2006</year><volume>17</volume><issue>6</issue><fpage>691</fpage><lpage>694</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1540-8167.2006.00501.x">http://dx.doi.org/10.1111/j.1540-8167.2006.00501.x</ext-link><pub-id pub-id-type="pmid">16836727</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>K</given-names></name></person-group><article-title>C-reactive protein (CRP)-lowering agents</article-title><source>Cardiovasc Drug Rev</source><year>2006</year><volume>24</volume><issue>1</issue><fpage>33</fpage><lpage>50</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1527-3466.2006.00033.x">http://dx.doi.org/10.1111/j.1527-3466.2006.00033.x</ext-link><pub-id pub-id-type="pmid">16939632</pub-id></element-citation></ref></ref-list></back></article>